BiomX (PHGE) Receives a Buy from Chardan Capital


Chardan Capital analyst Keay Nakae reiterated a Buy rating on BiomX (PHGE) yesterday and set a price target of $28.00. The company’s shares closed last Monday at $6.19.

According to TipRanks.com, Nakae is a 5-star analyst with an average return of 23.5% and a 47.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Arrowhead Pharmaceuticals, and Adverum Biotechnologies.

Currently, the analyst consensus on BiomX is a Strong Buy with an average price target of $24.33, implying a 293.7% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.

See today’s analyst top recommended stocks >>

BiomX’s market cap is currently $148M and has a P/E ratio of -4.70. The company has a Price to Book ratio of 2.72.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts